Vivian Fonseca, MD
Endocrinology, Diabetes & Metabolism · New Orleans, LANPI 1346356037
Payments from drug & device makers
Across 582 payments — averaging $1203.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi-aventis U.S. LLC$158K
- Asahi Kasei Therapeutics Corporation$87K
- Lilly USA, LLC$82K
- Abbott$81K
- Corcept Therapeutics$70K
- Novo Nordisk$46K
- plus $177K from 32 others
Across 15 payments — averaging $577.52 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sanofi-aventis U.S. LLC$9K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi-aventis U.S. LLC | 65 | $157,794 |
| Asahi Kasei Therapeutics Corporation | 6 | $87,000 |
| Lilly USA, LLC | 112 | $82,181 |
| Abbott | 120 | $81,174 |
| Corcept Therapeutics | 68 | $69,679 |
| Novo Nordisk | 34 | $45,781 |
| Gilead | 10 | $25,461 |
| Takeda | 5 | $25,050 |
| Bayer | 31 | $22,178 |
| Boehringer Ingelheim | 13 | $17,634 |
| Regeneron | 21 | $16,031 |
| Pfizer | 4 | $10,255 |
| Eli Lilly | 6 | $9,600 |
| Beckman Coulter, Inc. | 1 | $6,500 |
| Idorsia Pharmaceuticals US Inc | 6 | $5,614 |
| AstraZeneca | 5 | $5,162 |
| Boehringer Ingelheim Pharma GmbH & Co.kg | 38 | $4,873 |
| Alfasigma USA, Inc. | 1 | $4,339 |
| AbbVie | 1 | $3,875 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $3,540 |
| Scpharmaceuticals Inc. | 2 | $3,132 |
| Alnylam Pharmaceuticals Inc. | 1 | $2,750 |
| Dr.reddy's Laboratories,inc. | 1 | $2,625 |
| Esperion Therapeutics, Inc. | 8 | $2,057 |
| Hikma Pharmaceuticals USA | 1 | $2,000 |
| CSL Behring | 1 | $1,635 |
| Novo Nordisk AS | 2 | $740 |
| Vertex | 1 | $500 |
| Madrigal Pharmaceuticals | 5 | $459 |
| Dexcom, Inc. | 2 | $232 |
| Zealand Pharma US, Inc. | 1 | $189 |
| Astrazeneca UK Limited | 1 | $96 |
| Regeneron Healthcare Solutions, Inc. | 1 | $95 |
| Sanofi | 1 | $90 |
| Amarin Pharma, Inc. | 1 | $35 |
| Merck | 2 | $33 |
| Ascendis Pharma Endocrinology Inc | 1 | $24 |
| Amgen | 1 | $14 |
How this compares
$700,423 in reported general payments places this provider in the 95th percentile of 95 endocrinology, diabetes & metabolism providers in Louisiana.
See all endocrinology, diabetes & metabolism providers in Louisiana →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other endocrinology, diabetes & metabolism in New Orleans
- Dragana LovreNew Orleans$231K
- Lawrence BlondeNew Orleans$190K
- Bryan GrissettNew Orleans$8K
- Melina Roman-GerardinoNew Orleans$7K
- Mariam MenhemNew Orleans$5K
- Nyrene HaqueNew Orleans$5K
- Sarah SternliebNew Orleans$2K
- Suneeta GanjiNew Orleans$2K
- Tuan Huy TranMetairie$2M
- Harold MillerHammond$1.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.